Clinical Trials Logo

Severe Sepsis and Septic Shock clinical trials

View clinical trials related to Severe Sepsis and Septic Shock.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02391792 Recruiting - Clinical trials for Severe Sepsis and Septic Shock

Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance

Start date: March 2013
Phase: N/A
Study type: Observational [Patient Registry]

Microparticules (MPs) result from plasma cell membrane remodeling and shedding after cell stimulation or apoptosis. MPs are know recognized as a pool of bioactive messengers with merging role in pathophysiology of immune and cardiovascular diseases. MPs have been characterized during septic shock and may contribute to dissemination of pro-inflammatory and procoagulant mediators. This a prospective observational study of circulating MPs and blood coagulation in septic shock patients admitted in medical intensive care units (ICUs) of four tertiary hospitals at baseline (D1, D2, D3, D4, D7).

NCT ID: NCT02300415 Recruiting - Clinical trials for Severe Sepsis and Septic Shock

Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.

PREDI
Start date: December 2014
Phase: N/A
Study type: Observational

Severe sepsis and sepsis shock are common in emergency department, with a high mortality rate. The potential severity of this disease impose a diagnosis as early as possible to start antibiotic therapy and hemodynamic support. Conventional biomarkers are an important support for the emergency physician. However, comparison of sensitivity and specificity for new biomarkers, like presepsine, suggests that they can be more efficient in this area. In this single-center, prospective, non-interventional study, we propose to compare the sensitivity of presepsine to that of lactate for the diagnosis of severe sepsis and septic shock We emit to main hypothesis that the sensitivity of presepsine is higher than that of lactate for the diagnosis of severe sepsis.